Information For Veterinarians
Canvax is an autologous cancer vaccine platform designed to stimulate anti-tumour immunity using antigens derived from the patient’s own tumour, together with additional immune-enhancing components. By combining autologous tumour lysate with selected gentle immunostimulatory adjuvants, Canvax aims to improve immune recognition of tumour-associated antigens and promote a broader, more effective anti-cancer response.
This therapy is intended for use in selected canine cancer patients where a personalised immunotherapy approach is desirable, particularly in cases at risk of recurrence, progression, or metastatic disease. Canvax has induced growth retardation, partial and complete remissions in a variety of canine solid tumours during clinical trials.
Oksa A 2025 Novel Immunotherapeutics in the treatment of cancer in pet dogs an investigation into the tumour microenvironment PHD Thesis University of Queensland
How It Works
Many tumours evade immune detection by suppressing antigen presentation and creating an immunologically tolerant microenvironment. Canvax is designed to overcome this by presenting the immune system with a complex mixture of patient-specific tumour antigens alongside adjuvants intended to amplify immune activation and facilitate antigen uptake.
Because the vaccine is derived from the individual dog’s own tumour, it has the theoretical advantage of reflecting the unique antigenic profile of that cancer rather than relying on generic tumour targets. The inclusion of additional immune stimulants is intended to strengthen both priming and downstream adaptive anti-tumour responses.
The goal is to support systemic immune surveillance against residual, microscopic, or metastatic disease in a way that is tailored to the individual patient.
Key Features
- Personalised autologous vaccine using the dog’s own tumour antigens
- Enhanced with additional immune-stimulating adjuvant technology
- Gentle and well tolerated formulation designed to promote strong immune priming
- Intended for integration into multimodal veterinary oncology care
- Non-cytotoxic and residue-free from a chemotherapy perspective
- Potentially useful in high-risk, recurrent, or metastatic-prone cancers
- Individualised approach aligned with precision veterinary oncology
- Suitable for use in primary care practice and specialist settings
- Safe for the patient’s family and veterinary care team: being immune based the vaccine does not produce any toxic residues or metabolites.
Which Patients May Benefit?
Canvax may be considered for dogs with:
- Cancers where autologous tumour tissue is available for vaccine manufacture
- High-risk tumours with recurrence or metastatic potential
- Melanoma, mast cell tumour, lymphoma, and other cancers where immune engagement is desirable
- Patients managed with surgery, radiation, or other standard therapies where an adjunctive immunotherapy may be beneficial
- Owners seeking an individualised, immune-based oncology option
- Treatment approach for animals which have limited standard of care options due to local availability or concern regarding chemotherapy residues
Canvax is most appropriate where personalised vaccine preparation is feasible and where the patient’s clinical condition supports a staged immunotherapy plan.
Safety And Tolerability
As an autologous vaccine-based therapy, Canvax is expected to be generally well tolerated, with most adverse effects likely to reflect normal immune stimulation. These may include transient local swelling, discomfort at the injection site, mild pyrexia, lethargy, or short-duration inflammatory responses. In clinical trials, the gentle immune stimulants within Canvax were extremely well tolerated by a variety of canine oncology patients.
Because Canvax incorporates active immune adjuvants, clinicians should use standard caution in patients with marked systemic compromise, severe concurrent illness, or situations where inflammatory reactions could create unacceptable risk.
A Practical Advanced Immunotherapy For Today’s Veterinary Patients
Canvax represents an advanced personalised immunotherapy option for veterinary cancer patients. By pairing autologous tumour-derived antigen with additional immune activation technology, this platform is intended to provide a more immunologically assertive vaccine strategy for cases where enhanced immune engagement is desired.
This therapy is designed for veterinary use only and should be administered within an informed and appropriately monitored oncology framework.
Our autologous vaccine therapy (Canvax) is not a registered veterinary product and must therefore be used off label. Its administration is restricted to registered veterinarians, who must exercise independent clinical judgment, ensure appropriate case selection, and obtain informed owner consent in accordance with relevant state and territory veterinary legislation and professional standards.
As with all off-label therapies, responsibility for safe use, monitoring, and adverse event management rests with the treating veterinarian.
Considerations For Administration
Canvax is suitable for selected canine cancer patients with:
- confirmed diagnosis and appropriate clinical staging,
- available tumour tissue for autologous vaccine preparation,
- a clinical setting in which enhanced immune priming is desirable,
- expected survival sufficient to allow vaccine-induced immunity to develop, and
- owners who understand the personalised, off-label nature of the therapy.
As with any autologous product, tumour sample quality and case selection are critical. Canvax should be integrated thoughtfully with other treatments and with attention to timing relative to surgery, biopsy, chemotherapy, radiation, corticosteroid exposure, and overall immune competence.
How To Administer Canvax Autologous Vaccine For Dogs With Cancer
- Confirm tumour diagnosis and clinical suitability for autologous vaccine therapy.
- Collect and submit representative tumour tissue according to the specified handling protocol. *FREEZE TUMOUR TISSUE* (NOT in formalin)
- Ensure the tissue submitted is sufficient in quality and quantity for patient-specific vaccine manufacture.
- Canvax must only be administered to the individual patient from which the tumour tissue was derived.
- Store the dispensed product exactly as directed and maintain cold-chain conditions where required.
- Administer using sterile technique via the prescribed route and dosing schedule.
- Additional vaccine components or adjuvant fractions should be handled and administered exactly as dispensed.
- Avoid unnecessary immunosuppressive medications around the time of treatment where clinically feasible.
- Patients should be clinically assessed prior to each administration to confirm suitability to proceed.
- Monitor patients for 15–30 minutes after vaccination for immediate adverse effects.
- Inform owners that mild local and systemic post-vaccination reactions may occur as part of immune activation.
- Continue standard staging, surveillance, and oncology follow-up after treatment.
- Canvax is intended as an adjunctive personalised immunotherapy and should not replace indicated surgery or other standard-of-care treatments.
- Response should be assessed in the context of the individual cancer type, disease burden, and concurrent therapies.
- Use only under veterinary supervision with informed owner consent.
